Skin Cancer Prevention Tips from the Skin Cancer Foundation (May 17, 2017)

The development of skin cancer is certainly a risk for any individual, but particularly for those of us who spend time in the outdoors. As summer approaches it’s important to keep in mind that by taking certain steps to protect yourself from the sun,... Continue Reading

Check It Out: May is Skin Cancer Awareness Month (May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

FDA Approves Bavencio as First Treatment for Merkel Cell Cancer (March 31, 2017)

The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior... Continue Reading

Epacadostat Plus Keytruda® Appears Effective in Melanoma (October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery,... Continue Reading

Promising Activity of Pembrolizumab in Merkel Cell Carcinoma (June 14, 2016)

Treatment of 26 patients with advanced previously untreated Merkel cell carcinoma with Keytruda® (pembrolizumab) every three weeks resulted in an overall response rate of 56% suggesting this novel therapy could represent a new treatment option for these... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The... Continue Reading

National “Check Yourself to Protect Yourself ALL YEAR” Campaign Highlights Need for Year-Round Skin Cancer Prevention (November 12, 2015)

Although one in five Americans will get skin cancer in their lifetimes, 65 percent of people of color don’t believe they are at risk and face lower survival rates as a result. To change these odds, the cancer organization Patients Rising will use... Continue Reading

Patients with Multiple Squamous Cell Carcinomas Should be Frequently Monitored (October 21, 2015)

Patients with multiple sites of cutaneous squamous cell carcinoma (a type of skin cancer) have a significantly increased risk of developing a recurrence or spread to their lymph nodes, warranting frequent follow-up visits to their dermatologist. These... Continue Reading

Food and Drug Administration approves Odomzo for treatment of basal cell carcinoma (August 13, 2015)

The U. S. Food and Drug Administration approved Odomzo® (sonidegib, formerly LDE225) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Latest Skin Cancer News By Stage


General Skin Cancer

Check It Out: May is Skin Cancer Awareness Month (May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Promising Activity of Pembrolizumab in Merkel Cell Carcinoma (June 14, 2016)

Treatment of 26 patients with advanced previously untreated Merkel cell carcinoma with Keytruda® (pembrolizumab) every three weeks resulted in an overall response rate of 56% suggesting this novel therapy could represent a new treatment option for these... Continue Reading

National “Check Yourself to Protect Yourself ALL YEAR” Campaign Highlights Need for Year-Round Skin Cancer Prevention (November 12, 2015)

Although one in five Americans will get skin cancer in their lifetimes, 65 percent of people of color don’t believe they are at risk and face lower survival rates as a result. To change these odds, the cancer organization Patients Rising will use... Continue Reading

Patients with Multiple Squamous Cell Carcinomas Should be Frequently Monitored (October 21, 2015)

Patients with multiple sites of cutaneous squamous cell carcinoma (a type of skin cancer) have a significantly increased risk of developing a recurrence or spread to their lymph nodes, warranting frequent follow-up visits to their dermatologist. These... Continue Reading

Food and Drug Administration approves Odomzo for treatment of basal cell carcinoma (August 13, 2015)

The U. S. Food and Drug Administration approved Odomzo® (sonidegib, formerly LDE225) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates... Continue Reading

More General Skin Cancer

Skin Cancer Overview

Surgery May Not Be Best in Elderly Patients with Nonfatal Skin Cancer (June 28, 2013)

Although skin cancer is often treated with surgery, older patients with a limited life expectancy may not benefit from this treatment approach because they may endure complications and not live long enough to benefit from the treatment, according to the... Continue Reading

More Skin Cancer Overview